Purpose

Somatostatin analogues (SSAs) can slow down the growth of neuroendocrine tumors. However, the mechanism remains unclear. Recent studies on patients with acromegaly suggest that SSAs may induce apoptosis, increase autophagy, and decrease cell proliferation of pituitary adenoma. Ki-67-labeling index is a marker of cellular proliferation; therefore, decreased levels are associated with inhibition of proliferation. The aim of this study was to evaluate and compare the Ki-67-labeling index of GH-secreting pituitary adenoma tissues in patients who had undergone pituitary surgery twice due to residual or recurrent tumors and had received SSA treatment between the two surgeries.

Method

Thirty acromegaly patients who met the above criteria were identified and evaluated for the demographic, clinical and radiological features retrospectively. Surgical pathology samples of each operation were stained for Ki-67 and evaluated blindly by a staff pathologist specialized in pituitary diseases.

Results

Among patients who received SSA treatment between the first and second operations, the Ki-67 index of the adenoma at the second operation was significantly lower than the Ki-67 index at the first operation. There were no differences in clinical and radiological prognostic markers between the groups with decreased and unchanged Ki-67 index.

Conclusion

We concluded that SSA treatment appears to decrease Ki-67 proliferation index independent of tumor features, SSA type, dose and treatment duration. This result suggests that SSA treatment may decrease cellular proliferation, supporting the previous studies.

中文翻译：

---

生长抑素类似物对GH分泌腺瘤中Ki-67水平的影响。

目的

生长抑素类似物（SSA）可以减缓神经内分泌肿瘤的生长。但是，机制尚不清楚。对肢端肥大症患者的最新研究表明，SSA可能诱导垂体腺瘤凋亡，增加自噬并降低细胞增殖。Ki-67标记指数是细胞增殖的标志。因此，水平降低与增殖抑制有关。这项研究的目的是评估和比较因残留或复发性肿瘤而进行过两次垂体手术并在两次手术之间接受SSA治疗的患者中，GH分泌的垂体腺瘤组织的Ki-67标记指数。

方法

鉴定出满足上述标准的30例肢端肥大症患者，并对其人口统计学，临床和放射学特征进行回顾性评估。对每个手术的手术病理学样品进行Ki-67染色，并由专门从事垂体疾病的病理学家进行盲目评估。

结果

在第一次和第二次手术之间接受SSA治疗的患者中，第二次手术时腺瘤的Ki-67指数显着低于第一次手术时的Ki-67指数。Ki-67指数降低和不变的两组之间的临床和放射学预后指标无差异。

结论

我们得出的结论是，SSA治疗似乎可降低Ki-67增殖指数，而与肿瘤特征，SSA类型，剂量和治疗持续时间无关。这一结果表明，SSA治疗可能会降低细胞增殖，从而支持先前的研究。